FY2020 EPS Estimates for Curis Inc. (CRIS) Increased by SunTrust Banks
Curis Inc. (NASDAQ:CRIS) – Equities research analysts at SunTrust Banks upped their FY2020 earnings per share (EPS) estimates for Curis in a research note issued on Tuesday. SunTrust Banks analyst P. Lawson now expects that the brokerage will earn $0.06 per share for the year, up from their previous estimate of $0.03.
CRIS has been the topic of several other research reports. Zacks Investment Research raised shares of Curis from a “sell” rating to a “hold” rating in a report on Tuesday, October 4th. Robert W. Baird reissued an “outperform” rating and set a $7.00 price objective on shares of Curis in a report on Wednesday, September 7th. FBR & Co reissued a “buy” rating on shares of Curis in a report on Thursday, September 8th. Finally, RBC Capital Markets set a $7.00 price objective on shares of Curis and gave the stock a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $5.05.
Curis (NASDAQ:CRIS) traded down 3.63% on Thursday, reaching $2.92. 610,165 shares of the company’s stock were exchanged. The firm’s market capitalization is $378.06 million. Curis has a 12 month low of $1.25 and a 12 month high of $3.42. The firm has a 50-day moving average of $2.26 and a 200-day moving average of $1.87.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/fy2020-eps-estimates-for-curis-inc-cris-increased-by-suntrust-banks.html
Curis (NASDAQ:CRIS) last posted its earnings results on Thursday, August 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). The firm earned $1.70 million during the quarter, compared to analyst estimates of $2.05 million. Curis had a negative net margin of 526.72% and a negative return on equity of 65.51%. Curis’s revenue was down 19.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.06) EPS.
In other news, major shareholder Discovery Technologie Aurigene bought 10,208,333 shares of the stock in a transaction dated Wednesday, September 7th. The shares were bought at an average cost of $2.40 per share, with a total value of $24,499,999.20. Following the completion of the transaction, the insider now directly owns 27,328,464 shares of the company’s stock, valued at $65,588,313.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 6.09% of the stock is owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the stock. TFS Capital LLC raised its stake in Curis by 92.4% in the second quarter. TFS Capital LLC now owns 425,243 shares of the company’s stock worth $663,000 after buying an additional 204,278 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Curis during the second quarter worth approximately $312,000. Janney Montgomery Scott LLC bought a new stake in Curis during the second quarter worth approximately $310,000. Jacobs Levy Equity Management Inc. bought a new stake in Curis during the first quarter worth approximately $248,000. Finally, State Street Corp raised its stake in Curis by 8.7% in the second quarter. State Street Corp now owns 1,579,103 shares of the company’s stock worth $2,464,000 after buying an additional 126,694 shares during the last quarter. 52.36% of the stock is owned by institutional investors and hedge funds.
Curis Company Profile
Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.